SCHEMBL16285258

SCHEMBL16285258

CC(=O)/C(=C\c1cccc(Cl)c1)C(=O)OC(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
GLO1 Q04760 2/20 0.43
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
PTGS2 P35354 1/20 0.41
FBP1 P09467 1/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
AKR1C3 P42330 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5754740 0.84 GLO1 (0.46) HPGDALOX15GLO1CYP1A2CYP2C9
SCHEMBL5753353 0.84 GLO1 (0.46) HPGDALOX15GLO1CYP1A2CYP2C9
SCHEMBL6960592 0.84 GLO1 (0.46) HPGDGLO1CYP1A2CYP2C9PTGS2
SCHEMBL6960584 0.84 GLO1 (0.46) HPGDGLO1CYP1A2CYP2C9PTGS2
SCHEMBL5753360 0.84 GLO1 (0.46) HPGDALOX15GLO1CYP1A2CYP2C9
SCHEMBL11547520 0.83 GLO1 (0.57) GLO1CYP1A2CYP2C9PTGS2FBP1
SCHEMBL15026456 0.83 MAPT (0.45) GLO1CYP1A2CYP2C9PTGS2FBP1
SCHEMBL15026370 0.81 GLO1 (0.65) HPGDGLO1CYP1A2CYP2C9PTGS2
SCHEMBL2424030 0.81 GLO1 (0.65) HPGDGLO1CYP1A2CYP2C9PTGS2
SCHEMBL2424031 0.81 GLO1 (0.65) HPGDGLO1CYP1A2CYP2C9PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9284330-B2 1,4-dihydro-naphthyridine derivative and pharmaceutical composition and use thereof JIANGSU SIMOVAY PHARMACEUTICAL CO., LTD. (CN) 2016-03-15 US disclosed
US-20140364443-A1 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF JIANGSU SIMOVAY PHARMACEUTICAL CO., LTD. (CN) 2014-12-11 US disclosed
US-20140364443-A1 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF JIANGSU SIMOVAY PHARMACEUTICAL CO., LTD. (CN) 2014-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364443-A1 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF ACHE, BACE1, CACNA1D HPGD 182/4885ALOX15 1952/4885GLO1 2229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.